These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21999628)

  • 1. Antiangiogenesis in myelodysplastic syndrome.
    Aguayo A; Armillas-Canseco FM; Martínez-Baños D
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1044-52. PubMed ID: 21999628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
    Oh ST; Gotlib J
    Curr Hematol Malig Rep; 2008 Jan; 3(1):10-8. PubMed ID: 20425441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to the treatment of myelodysplasia.
    List AF
    Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biospecific agents for the treatment of myelodysplastic syndromes.
    Gotlib J; Greenberg PL
    J Natl Compr Canc Netw; 2003 Oct; 1(4):473-80. PubMed ID: 19774739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
    Aguayo A
    Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Sekeres MA
    Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
    Lu J; Jin J; Xu WL
    Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Sekeres MA
    Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in myelodysplastic syndrome.
    Melchert M; List A
    Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for treatment of multiple myeloma.
    Bruno B; Rotta M; Giaccone L; Massaia M; Bertola A; Palumbo A; Boccadoro M
    Lancet Oncol; 2004 Jul; 5(7):430-42. PubMed ID: 15231250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
    Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
    Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience with antiangiogenic therapy in leukemia.
    Wellbrock J; Fiedler W
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1053-68. PubMed ID: 21999626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational research in myelodysplastic syndromes.
    Raza A; Qawi H; Mehdi M; Mumtaz M; Galili N
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E2. PubMed ID: 16027100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
    Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
    Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
    List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
    Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.